Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Improved Outcomes in Metastatic Colon Cancer

Improved Outcomes in Metastatic Colon Cancer Colorectal Cancer Survival Gains and Novel Regimens Original Investigation Research 13. Selvaggi F, Cuocolo A, Sciaudone G, Maurea S, 17. Cancer Research UK. Which treatment for 22. Sargent DJ, Wieand HS, Haller DG, et al. Giuliani A, Mainolfi C. FGD-PET in the follow-up of advanced bowel cancer. http://www Disease-free survival versus overall survival as a recurrent colorectal cancer. Colorectal Dis. 2003;5 .cancerresearchuk.org/about-cancer/type/bowel primary end point for adjuvant colon cancer (5):496-500. -cancer/treatment/types/which-treatment-for studies: individual patient data from 20,898 -advanced-bowel-cancer. Accessed May 1, 2015. patients on 18 randomized trials. J Clin Oncol. 2005; 14. Gearhart SL, Frassica D, Rosen R, Choti M, 23(34):8664-8670. Schulick R, Wahl R. Improved staging with 18. Memorial Sloan Kettering Cancer Center. pretreatment positron emission tomography/ Colorectal Cancer: Treatment for Metastases. https: 23. Buyse M, Burzykowski T, Michiels S, Carroll K. computed tomography in low rectal cancer. Ann //www.mskcc.org/cancer-care/adult/colorectal Individual- and trial-level surrogacy in colorectal Surg Oncol. 2006;13(3):397-404. /treatment-metastases. Accessed May 1, 2015. cancer. Stat Methods Med Res. 2008;17(5):467-475. 15. McDermott PW. Industry perspective on clinical 19. Bartlett EK, Simmons KD, Wachtel H, et al. The 24. Elston J, Taylor RS. Use of surrogate outcomes investigative sites: maximizing sponsor return on rise in metastasectomy across cancer types http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Improved Outcomes in Metastatic Colon Cancer

Sargent, Daniel
JAMA Oncology , Volume 1 (6) – Sep 1, 2015
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/improved-outcomes-in-metastatic-colon-cancer-60fIgVpNrB
Publisher
American Medical Association
Copyright
Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2015.1789
pmid
26181004
Publisher site
See Article on Publisher Site

Abstract

Colorectal Cancer Survival Gains and Novel Regimens Original Investigation Research 13. Selvaggi F, Cuocolo A, Sciaudone G, Maurea S, 17. Cancer Research UK. Which treatment for 22. Sargent DJ, Wieand HS, Haller DG, et al. Giuliani A, Mainolfi C. FGD-PET in the follow-up of advanced bowel cancer. http://www Disease-free survival versus overall survival as a recurrent colorectal cancer. Colorectal Dis. 2003;5 .cancerresearchuk.org/about-cancer/type/bowel primary end point for adjuvant colon cancer (5):496-500. -cancer/treatment/types/which-treatment-for studies: individual patient data from 20,898 -advanced-bowel-cancer. Accessed May 1, 2015. patients on 18 randomized trials. J Clin Oncol. 2005; 14. Gearhart SL, Frassica D, Rosen R, Choti M, 23(34):8664-8670. Schulick R, Wahl R. Improved staging with 18. Memorial Sloan Kettering Cancer Center. pretreatment positron emission tomography/ Colorectal Cancer: Treatment for Metastases. https: 23. Buyse M, Burzykowski T, Michiels S, Carroll K. computed tomography in low rectal cancer. Ann //www.mskcc.org/cancer-care/adult/colorectal Individual- and trial-level surrogacy in colorectal Surg Oncol. 2006;13(3):397-404. /treatment-metastases. Accessed May 1, 2015. cancer. Stat Methods Med Res. 2008;17(5):467-475. 15. McDermott PW. Industry perspective on clinical 19. Bartlett EK, Simmons KD, Wachtel H, et al. The 24. Elston J, Taylor RS. Use of surrogate outcomes investigative sites: maximizing sponsor return on rise in metastasectomy across cancer types

Journal

JAMA Oncology – American Medical Association

Published: Sep 1, 2015

References

  • CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).
    Venook, AP; Niedzwiecki, D; Lenz, H-J
  • Colorectal cancer survival gains and novel treatment regimens: a systematic review and analysis [published online June 25, 2015].
    Jawed, I; Wilkerson, J; Prasad, V; Duffy, AG; Fojo, T
  • Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.
    Kopetz, S; Chang, GJ; Overman, MJ
  • Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.
    Shi, Q; de Gramont, A; Grothey, A
  • Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.
    de Gramont, A; Buyse, M; Abrahantes, JC
  • Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
    Bennouna, J; Sastre, J; Arnold, D